These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27527859)

  • 1. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
    Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
    Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
    Touil Y; Igoudjil W; Corvaisier M; Dessein AF; Vandomme J; Monté D; Stechly L; Skrypek N; Langlois C; Grard G; Millet G; Leteurtre E; Dumont P; Truant S; Pruvot FR; Hebbar M; Fan F; Ellis LM; Formstecher P; Van Seuningen I; Gespach C; Polakowska R; Huet G
    Clin Cancer Res; 2014 Feb; 20(4):837-46. PubMed ID: 24323901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
    Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
    Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
    Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
    Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
    Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
    Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
    Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
    Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic control of YAP and TAZ by the mevalonate pathway.
    Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
    Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP/TAZ at the Roots of Cancer.
    Zanconato F; Cordenonsi M; Piccolo S
    Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
    Konishi T; Schuster RM; Lentsch AB
    Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
    Pobbati AV; Hong W
    Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.